Biologic Therapy for Rheumatoid Arthritis in Bhubaneswar

Rheumatoid arthritis (RA) is an autoimmune condition in which the immune system mistakenly attacks the joints, causing inflammation, pain, swelling, and over time, joint damage. For many patients, conventional disease-modifying antirheumatic drugs (DMARDs) such as methotrexate provide adequate control. However, a significant proportion of RA patients do not achieve remission or low disease activity with these first-line agents.

Biologic DMARDs — often simply called “biologics” — represent the next step in RA treatment. These are laboratory-engineered proteins that precisely target specific molecules in the immune cascade responsible for driving joint inflammation. Unlike methotrexate or hydroxychloroquine, which broadly dampen immune activity, biologics act on defined molecular targets, making them more selective and often more effective for patients with moderate-to-severe, inadequately controlled RA.

At the Odisha Arthritis & Rheumatology Centre (OARC) in Bhubaneswar, Dr. Jyoti Ranjan Parida evaluates RA patients who may benefit from biologic therapy and guides them through the entire treatment pathway — from eligibility assessment to monitoring and long-term management.

Traditional DMARDs such as methotrexate, sulfasalazine, leflunomide, and hydroxychloroquine have been the backbone of RA treatment for decades. They work by broadly suppressing overactive immune pathways. They are effective, inexpensive, and well-studied, but they lack precision — they affect the immune system widely rather than at a specific inflammatory target.

Biologic DMARDs, by contrast, are protein-based therapies — monoclonal antibodies or fusion proteins — that block specific cytokines or immune cell interactions that have been identified as key drivers of RA inflammation. Because they intervene at a defined molecular point, they can achieve remission in patients who have not responded to conventional DMARDs, and they often act more quickly.

Biologic therapy is not the first treatment tried for RA. According to established national and international guidelines, biologics are considered when:

• The patient has moderate-to-severe active RA with persistently elevated disease activity scores
• An adequate trial of at least one conventional DMARD — usually methotrexate at therapeutic doses for 3 to 6 months — has not achieved satisfactory disease control
• Inflammatory markers (ESR, CRP) remain elevated and there is clinical evidence of active synovitis
• There is no contraindication to biologic therapy, including serious infection risk, active tuberculosis (TB), severe hepatitis B, or certain haematological conditions

In practice, this means biologics are used in a meaningful subset of RA patients — those whose disease remains aggressive despite conventional treatment. Eligibility is always assessed by a rheumatologist who considers the full clinical picture, not just one set of lab results.

Before starting biologic therapy, Dr. Parida conducts a thorough pre-treatment screening at OARC that includes TB testing (Mantoux test and/or IGRA), hepatitis B surface antigen and core antibody, a full blood count, liver function tests, and a review of recent infections and vaccinations.

Starting biologic therapy involves more preparation than switching a tablet, but for eligible patients the potential benefit — reduced inflammation, protected joints, and better quality of life — is significant.

Administration

Most biologics are given either as a self-administered subcutaneous (under-the-skin) injection — using a pre-filled syringe or auto-injector pen — or as an intravenous (IV) infusion given at a clinic. Subcutaneous biologics such as adalimumab or etanercept can be administered at home once patients are trained. IV infusions (rituximab, tocilizumab) are administered under medical supervision, typically in a day-care setting.

Monitoring

Regular monitoring is essential during biologic therapy. This typically includes:

• Blood counts (to detect cytopenias)
• Liver function tests (particularly if combined with methotrexate)
• Infection surveillance — patients on biologics have an increased risk of certain infections and should report fevers or illness promptly
• Disease activity assessments (DAS28 or CDAI scores) at each clinic visit to gauge treatment response

Expected Timeline

Many patients notice improvement in joint pain, swelling, and morning stiffness within 4 to 8 weeks of starting biologic therapy. Maximum benefit is often seen at 3 to 6 months. Disease activity is re-assessed at each clinic visit and the treatment plan adjusted accordingly. Some patients achieve sustained remission; others require ongoing therapy to maintain disease control.

Biologic therapy for RA is not a treatment to start or manage without specialist oversight. A number of factors make rheumatologist-led care essential:

• Accurate diagnosis and eligibility assessment: RA must be confirmed and disease severity properly quantified before biologic escalation can be justified.
• Pre-treatment screening: Missing TB or hepatitis B can lead to life-threatening reactivation once a biologic is started. This screening must be done correctly and interpreted in clinical context.
• Choice of agent: Not all biologics suit all patients. Comorbidities, serostatus, prior treatments, and practicalities (injection vs infusion, frequency) all inform the choice.
• Monitoring and dose adjustment: Long-term safety requires structured follow-up — something only a specialist clinic can provide.
• Managing side effects: Infusion reactions, injection-site reactions, and infection risk all need to be monitored and managed promptly.

At OARC in Bhubaneswar, Dr. Jyoti Ranjan Parida brings specialist rheumatology training to the management of complex RA cases, including patients on biologic and targeted synthetic DMARD therapy. OARC is one of the few dedicated rheumatology practices in Odisha offering structured biologic therapy evaluation and monitoring.

A legitimate concern for patients considering anti-TNF or other biologic therapy in Odisha is cost. Originator biologics can be expensive. However, biosimilar versions of several key RA biologics — including adalimumab, etanercept, rituximab, and tocilizumab — are now approved and available in India, significantly reducing the cost of treatment. Dr. Parida discusses biosimilar options with patients during consultation, helping them access effective therapy within realistic cost constraints.